Real-world effectiveness of erenumab in Japanese patients with migraine
Background: Real-world evidence of erenumab effectiveness in migraine patients in Asia with various comorbidities and multiple previous medication failures is still limited. Methods: A 6-month single-center cohort study of 45 patients with episodic or chronic migraine (CM) treated with erenumab was...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2024-02-01
|
| Series: | Heliyon |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2405844024025994 |
| _version_ | 1797267699005390848 |
|---|---|
| author | Keisuke Suzuki Shiho Suzuki Tomohiko Shiina Yasuo Haruyama Saro Kobayashi Mukuto Shioda Koichi Hirata |
| author_facet | Keisuke Suzuki Shiho Suzuki Tomohiko Shiina Yasuo Haruyama Saro Kobayashi Mukuto Shioda Koichi Hirata |
| author_sort | Keisuke Suzuki |
| collection | DOAJ |
| description | Background: Real-world evidence of erenumab effectiveness in migraine patients in Asia with various comorbidities and multiple previous medication failures is still limited. Methods: A 6-month single-center cohort study of 45 patients with episodic or chronic migraine (CM) treated with erenumab was conducted. In the cohort, 60.0% were switching from other calcitonin gene-related peptide monoclonal antibodies (CGRP mAbs), and 66.7% had ≥4 prophylaxis failures. The change in monthly migraine days (MMDs) from baseline and percentages of responders after treatment were calculated. Weekly migraine days (WMDs) were obtained at baseline and at months 1, 2 and 3 and were compared between weeks 2 and 4. Results: In total, 36%, 47%, and 63% of patients had a ≥30% response at 1, 3, and 6 months, respectively. The cumulative percentage of patients achieving a ≥30% response over 6 months was 85%. Early responders (average ≥ 30% response at 1–3 months) accounted for 37.8%, 55.6%, and 25.9% of the total, CGRP mAb-naïve, and CGRP mAb-switching groups, respectively. Late responders (average < 30% response at 1–3 months and average ≥ 30% response at 4–6 months) accounted for 46.4%, 37.5%, and 58.8% of nonearly responders in the total, CGRP mAb-naïve, and CGRP mAb-switching groups, respectively. Mild adverse reactions were observed in 5 patients (11.1%). Wearing-off, defined as an increase in the number of WMDs ≥2 between week 2 and week 4, was observed in 2.4–12.5% at months 1–3. Conclusion: Erenumab was effective in migraine patients. At least 4–6 months may be preferable for efficacy evaluation in patients switching to erenumab from other CGRP mAbs. |
| first_indexed | 2024-03-07T23:06:27Z |
| format | Article |
| id | doaj.art-c83c6edad29e4056bbfe231df1ee3371 |
| institution | Directory Open Access Journal |
| issn | 2405-8440 |
| language | English |
| last_indexed | 2024-04-25T01:20:44Z |
| publishDate | 2024-02-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Heliyon |
| spelling | doaj.art-c83c6edad29e4056bbfe231df1ee33712024-03-09T09:28:35ZengElsevierHeliyon2405-84402024-02-01104e26568Real-world effectiveness of erenumab in Japanese patients with migraineKeisuke Suzuki0Shiho Suzuki1Tomohiko Shiina2Yasuo Haruyama3Saro Kobayashi4Mukuto Shioda5Koichi Hirata6Department of Neurology, Dokkyo Medical University, Japan; Corresponding author. Department of Neurology, Dokkyo Medical University, 880 Kitakobayashi, Mibu, Shimotsuga, Tochigi, 321-0293, Japan.Department of Neurology, Dokkyo Medical University, JapanDepartment of Neurology, Dokkyo Medical University, JapanIntegrated Research Faculty for Advanced Medical Sciences, Dokkyo Medical University, JapanDepartment of Neurology, Dokkyo Medical University, JapanDepartment of Neurology, Dokkyo Medical University, JapanDepartment of Neurology, Dokkyo Medical University, JapanBackground: Real-world evidence of erenumab effectiveness in migraine patients in Asia with various comorbidities and multiple previous medication failures is still limited. Methods: A 6-month single-center cohort study of 45 patients with episodic or chronic migraine (CM) treated with erenumab was conducted. In the cohort, 60.0% were switching from other calcitonin gene-related peptide monoclonal antibodies (CGRP mAbs), and 66.7% had ≥4 prophylaxis failures. The change in monthly migraine days (MMDs) from baseline and percentages of responders after treatment were calculated. Weekly migraine days (WMDs) were obtained at baseline and at months 1, 2 and 3 and were compared between weeks 2 and 4. Results: In total, 36%, 47%, and 63% of patients had a ≥30% response at 1, 3, and 6 months, respectively. The cumulative percentage of patients achieving a ≥30% response over 6 months was 85%. Early responders (average ≥ 30% response at 1–3 months) accounted for 37.8%, 55.6%, and 25.9% of the total, CGRP mAb-naïve, and CGRP mAb-switching groups, respectively. Late responders (average < 30% response at 1–3 months and average ≥ 30% response at 4–6 months) accounted for 46.4%, 37.5%, and 58.8% of nonearly responders in the total, CGRP mAb-naïve, and CGRP mAb-switching groups, respectively. Mild adverse reactions were observed in 5 patients (11.1%). Wearing-off, defined as an increase in the number of WMDs ≥2 between week 2 and week 4, was observed in 2.4–12.5% at months 1–3. Conclusion: Erenumab was effective in migraine patients. At least 4–6 months may be preferable for efficacy evaluation in patients switching to erenumab from other CGRP mAbs.http://www.sciencedirect.com/science/article/pii/S2405844024025994MigraineErenumabCalcitonin gene-related peptide |
| spellingShingle | Keisuke Suzuki Shiho Suzuki Tomohiko Shiina Yasuo Haruyama Saro Kobayashi Mukuto Shioda Koichi Hirata Real-world effectiveness of erenumab in Japanese patients with migraine Heliyon Migraine Erenumab Calcitonin gene-related peptide |
| title | Real-world effectiveness of erenumab in Japanese patients with migraine |
| title_full | Real-world effectiveness of erenumab in Japanese patients with migraine |
| title_fullStr | Real-world effectiveness of erenumab in Japanese patients with migraine |
| title_full_unstemmed | Real-world effectiveness of erenumab in Japanese patients with migraine |
| title_short | Real-world effectiveness of erenumab in Japanese patients with migraine |
| title_sort | real world effectiveness of erenumab in japanese patients with migraine |
| topic | Migraine Erenumab Calcitonin gene-related peptide |
| url | http://www.sciencedirect.com/science/article/pii/S2405844024025994 |
| work_keys_str_mv | AT keisukesuzuki realworldeffectivenessoferenumabinjapanesepatientswithmigraine AT shihosuzuki realworldeffectivenessoferenumabinjapanesepatientswithmigraine AT tomohikoshiina realworldeffectivenessoferenumabinjapanesepatientswithmigraine AT yasuoharuyama realworldeffectivenessoferenumabinjapanesepatientswithmigraine AT sarokobayashi realworldeffectivenessoferenumabinjapanesepatientswithmigraine AT mukutoshioda realworldeffectivenessoferenumabinjapanesepatientswithmigraine AT koichihirata realworldeffectivenessoferenumabinjapanesepatientswithmigraine |